Geneva, Switzerland, April 11, 2024 – Addex Therapeutics (SIX and NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, today announced that it will report its full-year 2023 financial results on April 18, 2024. CEO Tim Dyer and Mikhail Kalinichev, Head of Translational Science, will speak to investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) will provide business updates and reviews of his Addex product pipeline on conference calls and webcasts. same day.
Title: Adex Therapeutics Announces Full Year 2023 Financial Results and Provides Company Update
Date: April 18, 2023
Time: 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT)
Join the conference call:
-
Participants must pre-register for the conference using the link below. Upon registration, each participant will be provided with a participant dial-in number and a unique personal PIN.
-
Participants must use the meeting access information provided in the email they received during registration no later than 10 minutes before the call start time. Participants can also use the Call Me feature instead of dialing their local dial-in number.
Webcast registration URL:
https://edge.media-server.com/mmc/p/x5teqtxq
Conference call registration URL: https://register.vevent.com/register/BI89ea15fb1edc42c5bba59bbd3f7ab1d3
About Adex Therapeutics:
Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological diseases. ADX71149 (mGlu2 positive allosteric modulator or his PAM), Adex's lead drug candidate, was co-developed with Janssen Pharmaceuticals and is in Phase 2 clinical trials for the treatment of epilepsy. His second clinical program at the company, Zipragrant (mGlu5 negative allosteric modulator or NAM), is being evaluated for future development in Parkinson's disease-associated dyskinesia and recovery after stroke/traumatic brain injury. His Addex partnership with Indivior on GABAB PAM is advancing multiple drug candidates through clinical candidate selection for substance use disorders. Under the agreement with Indivior, Addex is advancing his independent GABAB PAM program for chronic cough through clinical candidate selection. Addex also owns a 20% stake in Neurosterix LLC, a privately held company that is advancing a portfolio of allosteric modulator programs including M4 PAM for schizophrenia, mGlu7NAM for stress-related disorders, and mGlu2NAM for mild neurocognitive disorders . Adex's shares are listed on the Swiss SIX Exchange, and its American Depositary Shares, representing its shares, are listed on the Nasdaq Capital Market, trading on each exchange under the ticker symbol “ADXN.” For more information, please visit www.addextherapeutics.com.
contact address:
Appendix Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the use of proceeds from the offering. “may”, “would”, “could”, “would”, “should”, “expect”, “plan”, “anticipate”, “intend”, ” The words “believe,” “estimate,” “anticipate,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements. However, not all forward-looking statements contain these identifiable words. The forward-looking statements in this press release are based on management's current expectations and beliefs and may cause actual events or results to differ materially from those expressed or implied by the forward-looking statements. It is subject to a number of risks, uncertainties and important factors. Statements contained in this press release are subject to uncertainties, including, without limitation, those related to market conditions; These and other risks and uncertainties are discussed in Adex Therapeutics' Annual Report on Form 20-F for the year ended December 31, 2022, filed with the SEC on March 30, 2023. are detailed in the section entitled “Risk Factors''. the final prospectus supplement and accompanying prospectus and other filings that Adex Therapeutics may make with the SEC in the future; The forward-looking statements contained in this press release represent Adex Therapeutics' views only as of the date of this press release and should be relied upon as representing its views as of any subsequent date. Not. Addex Therapeutics expressly disclaims any obligation to update any forward-looking statements.
